Roche commits to diabetes testing and sees 2017 return to growth
By Ben Hirschler LONDON (Reuters) – Roche has no plans to sell its diabetes testing business, despite a pummeling in the past three years from U.S. price cuts, and the Swiss drugmaker expects the unit to return to sales growth in 2017. Roland Diggelmann, head of Roche diagnostics, said the fundamentals for blood glucose meters remained strong given the growing incidence of type 2 diabetes, which is linked to obesity, especially in emerging markets. Roche, best known for its cancer drugs, is also the world's biggest diagnostics company and the market leader in diabetes testing.
